Hostname: page-component-7c8c6479df-hgkh8 Total loading time: 0 Render date: 2024-03-28T20:35:12.780Z Has data issue: false hasContentIssue false

Prophylactic HPV vaccination: past, present, and future – CORRIGENDUM

Published online by Cambridge University Press:  29 April 2016

Rights & Permissions [Opens in a new window]

Abstract

Type
Corrigendum
Copyright
Copyright © Cambridge University Press 2016 

In Table 1 of the above-mentioned article [Reference Castle and Maza1] the units for ‘Vaccine composition’ (column 1, line 5) are incorrect. They should be µg, rather than mg.

In Figure 1, the orange bar for ‘ATP all cervical precancer’ should indicate 42·7%. In the caption for Figure 1, reference [29] should be [27]. The correct version of Figure 1 and caption are given below.

Fig. 1. A comparison of vaccine efficacy against targeted HPV type-related (purple bars) and all cervical precancer (CIN2, CIN3, or AIS) (orange bars) by 2vHPV [27], and 4vHPV [28], for the HPV-naive populations (TVC-naive and ATP, respectively) and the entire vaccinated cohort (TVC and ITT, respectively). TVC, Total vaccine cohort; ATP, attention to protocol; ITT, intention to treat.

The authors apologize for these errors.

References

REFERENCE

1. Castle, PE, Maza, M. Prophylactic HPV vaccination: past, present, and future. Epidemiology and Infection 2016; 144: 449468. doi:10.1017/S0950268815002198. Published online: 2 October 2015.Google Scholar
Figure 0

Fig. 1. A comparison of vaccine efficacy against targeted HPV type-related (purple bars) and all cervical precancer (CIN2, CIN3, or AIS) (orange bars) by 2vHPV [27], and 4vHPV [28], for the HPV-naive populations (TVC-naive and ATP, respectively) and the entire vaccinated cohort (TVC and ITT, respectively). TVC, Total vaccine cohort; ATP, attention to protocol; ITT, intention to treat.